Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine - Wikidata - awgldk - TriplyDB

Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine

Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine

http://www.wikidata.org/entity/Q28749695

about

sameAs

Age-related immunity to meningococcal serogroup C vaccination: an increase in the persistence of IgG2 correlates with a decrease in the avidity of IgG Timing of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age; an intervention study among Dutch teenagers Impact of meningococcal C conjugate vaccination campaign in Emilia-Romagna, Italy.Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands.Different Dynamics for IgG and IgA Memory B Cells in Adolescents following a Meningococcal Serogroup C Tetanus Toxoid Conjugate Booster Vaccination Nine Years after Priming: A Role for Priming Age?Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction The impact of prenatal exposure to parasitic infections and to anthelminthic treatment on antibody responses to routine immunisations given in infancy: Secondary analysis of a randomised controlled trial.Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years.Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence.Epidemiology and prevention of meningococcal disease: a critical appraisal of vaccine policies.Can we, should we, eradicate the meningococcus?Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience.Novel Intervention in the Aging Population: A Primary Meningococcal Vaccine Inducing Protective IgM Responses in Middle-Aged Adults.Kinetics of Meningococcal Serogroup C-Specific Functional Antibody Levels Up to 15 Years after a Single Immunization with a Meningococcal Serogroup C Conjugate Vaccine during Adolescence.Need for Optimisation of Immunisation Strategies Targeting Invasive Meningococcal Disease in the Netherlands.Disease Burden of Invasive Meningococcal Disease in the Netherlands Between June 1999 and June 2011: A Subjective Role for Serogroup and Clonal Complex.Kinetics of the long-term antibody response after meningococcal C vaccination in patients with juvenile idiopathic arthritis: a retrospective cohort study.Prevalence and decay of maternal pneumococcal and meningococcal antibodies: A meta-analysis of type-specific decay rates.Challenges and opportunities for Meningococcal vaccination in the developing world.Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018.Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine.

P2860

Q28741100-4DBFD061-223D-4AC6-BF9E-DAB8AF819A21 Q33806774-037BEF5E-FE13-4A5C-8C59-9C3B10E3488B Q34033849-75DC1B4A-5496-4FB9-AAD2-B0514643A0C2 Q34153704-1A4A0A06-4C85-48C0-A37F-A818D7DE50B7 Q35803424-CEA011AE-6DC1-44B2-B76A-F937C35E08B9 Q36154716-1A12D326-D5A5-469F-9122-0B65C1DAE9B0 Q36274121-3B987730-6975-43CE-A87A-68296513D1FD Q36781534-E7C6B7F3-5B8E-406B-B504-3FCE1DCC81C9 Q36849830-E733A20B-112F-455A-BC53-3C0A8159E864 Q36849834-A3838913-1422-49D1-B95F-753C64EC47F1 Q36891586-BFD5BBB8-0C69-46FC-818B-BDF3365895E1 Q37505414-EB439FBD-CA20-4B9A-B2A2-E2C2C72CFE07 Q37956384-4026943D-FA5E-402B-9D0E-E9E6ACDDA5C9 Q38011316-D870FF1A-4705-44EC-AE7B-0E0018730CB3 Q38367830-D808655D-DDFA-4C57-B333-D3F6EEFEEE4F Q38647852-27B30FAF-C073-4E95-911D-16BAF362FE89 Q38791439-1ED86318-F389-4998-8191-5670EF465ECD Q38931495-756F898E-0688-4234-AB52-23250F1240DC Q40783765-A287BAE0-3915-4F34-B524-6B01B4F472A6 Q42270579-7775AFA3-B9FB-451B-839A-DA9218E5EAE5 Q42278590-006E27B1-B4DA-4EF4-BDCE-943E92C0F44E Q49377063-6279612D-AC1C-4A27-B3EA-C0E4FA2B00E2 Q52310393-B37E01EB-4FAB-42BA-94F2-3C05B3D2D664 Q54963381-4EC3B53B-5DA1-454D-88FE-DBADA9C16242

P2860

Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine

http://www.wikidata.org/entity/Q28749695

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Immunity against Neisseria men ...... ingococcal c conjugate vaccine

@ast

Immunity against Neisseria men ...... ingococcal c conjugate vaccine

@en

Immunity against Neisseria men ...... ingococcal c conjugate vaccine

@nl

type

label

Immunity against Neisseria men ...... ingococcal c conjugate vaccine

@ast

Immunity against Neisseria men ...... ingococcal c conjugate vaccine

@en

Immunity against Neisseria men ...... ingococcal c conjugate vaccine

@nl

prefLabel

Immunity against Neisseria men ...... ingococcal c conjugate vaccine

@ast

Immunity against Neisseria men ...... ingococcal c conjugate vaccine

@en

Immunity against Neisseria men ...... ingococcal c conjugate vaccine

@nl

P1433

Q28749695-51142E87-FD17-4A65-BE90-5B773DBDD50E

P1476

Q28749695-73BA35F5-C76C-4B70-883B-DFE60209E9AC

P2093

Q28749695-316301C8-3F83-49BA-B56D-3F2CD0FBC35F

Q28749695-6D42DF98-49BF-4F14-B156-3697EE4B2908

Q28749695-A4C03239-1960-4645-9E82-22A2545ED97C

Q28749695-B6F206F8-6691-4E7A-98D6-90F7F334E8A0

Q28749695-BA48282C-8F04-42D4-BE5C-79CBF3696355

Q28749695-BB838C93-01F1-433A-8FDB-F60496AB0679

Q28749695-D4663F12-027C-402F-B0F8-712771EFF535

Q28749695-DAEA021D-11AD-46A5-8985-19EA8E10A213

Q28749695-DDC1A025-9909-4FB4-8983-A72540214D41

P2860

Q28749695-05F5BA73-2A30-46EB-9A9D-7D9952E815DF

Q28749695-07BA0FB6-FFD2-4271-88DC-CB9805BC626C

Q28749695-0C834353-EDAA-4DCC-A4D1-7437F4170AD3

Q28749695-1675E2D2-2318-478D-BCA9-65F29A304F66

Q28749695-1AB57BF0-9156-489E-A80A-85B89502FFCB

Q28749695-1B451462-1F51-4FFB-88AE-80E7FC8F4321

Q28749695-24450746-34E2-4933-860D-C1967FA4D19E

Q28749695-2582276B-B3E1-4102-8FDF-75E385227FCD

Q28749695-2620B314-D71C-43BF-A576-08B3AD61F522

Q28749695-4CFF0152-FC50-45B0-AB58-68BB8C723BEF

P304

Q28749695-C2CF411E-A214-4C95-8495-1CBE6771A7E3

P31

Q28749695-CBD5E3AA-D3C1-49AA-86C7-843912548A26

P356

Q28749695-48517802-0292-45B6-AF32-90540B1B14EB

P407

Q28749695-13BBB912-D723-4CFB-8C5E-2DCCC2462F05

P433

Q28749695-C788A506-95AC-4C5E-A541-663B2076F097

P478

Q28749695-0F4486D5-A273-4A5A-9C51-F99BAA8217CB

P577

Q28749695-6E33C44E-E40A-4289-8F4A-AE1A24AF27C5

P5875

Q28749695-1E31D84B-A6C8-49A7-9D12-3BD6508D0CD2

P698

Q28749695-E52BD961-4BF7-4C07-98A7-CC3BD5E3E3FC

P921

Q28749695-096373AC-6663-4696-83DA-CA7A723637AF

P932

Q28749695-B5DE3EBB-704D-4854-A603-C73ADFDCF28C

P356

JOURNAL.PONE.0012144

P1433

P1476

Immunity against Neisseria men ...... ingococcal c conjugate vaccine

@en

P2093

Elisabeth A M Sanders

http://www.w3.org/2001/XMLSchema#string

Fiona R M van der Klis

http://www.w3.org/2001/XMLSchema#string

Guy A M Berbers

http://www.w3.org/2001/XMLSchema#string

Hester E de Melker

http://www.w3.org/2001/XMLSchema#string

Liesbeth Mollema

http://www.w3.org/2001/XMLSchema#string

Pieter G M van Gageldonk

http://www.w3.org/2001/XMLSchema#string

Richarda M de Voer

http://www.w3.org/2001/XMLSchema#string

Rutger M Schepp

http://www.w3.org/2001/XMLSchema#string

Sabine C de Greeff

http://www.w3.org/2001/XMLSchema#string

P2860

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

Second national serum bank for population-based seroprevalence studies in the Netherlands.

Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vacc

Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity

Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.

Development of interleukin-12-producing capacity throughout childhood

Bacillus pumilus polysaccharide cross-reactive with meningococcal group A polysaccharide.

Enteric bacteria cross-reactive with Neisseria meningitidis groups A and C and Diplococcus pneumoniae types I and 3

Polysaccharides of the genus Bacillus cross-reactive with the capsular polysaccharides of Diplococcus pneumoniae type 3, Haemophilus influenzae type b, and Neisseria meningitidis group A.

Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine

P304

e12144

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0012144

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45800509

http://www.w3.org/2001/XMLSchema#string

P698

20730091

http://www.w3.org/2001/XMLSchema#string

P921

Neisseria meningitidis

P932

2921331

http://www.w3.org/2001/XMLSchema#string